8-K: Olema Pharmaceuticals Announces FDA Clearance for OP-3136 and Positive Palazestrant Clinical Trial Update

Olema Pharmaceuticals has received FDA clearance for its new drug OP-3136 and reported promising results from a Phase 1b/2 study of palazestrant in combination with ribociclib for breast cancer.

Summary

• Olema Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for OP-3136, a novel small molecule KAT6 inhibitor, with a Phase 1 clinical trial expected to begin in early 2025.
• The company also released updated clinical results from its Phase 1b/2 study of palazestrant combined with ribociclib in patients with ER+/HER2advanced or metastatic breast cancer.
• The study included 62 patients, with 56 receiving the recommended Phase 2 dose of 120 mg of palazestrant daily, plus 600 mg of ribociclib daily.
• The majority of patients (77%) had received prior endocrine therapy, and 74% had prior treatment with a CDK4/6 inhibitor.
• The combination showed promising clinical activity, including tumor responses and prolonged disease stabilization, with a 6-month progression-free survival (PFS) rate of 73% across all patients.
• In patients with prior CDK4/6i treatment, the 6-month PFS rate was 68%, while ESR1 mutant patients had a 6-month PFS rate of 81% and ESR1 wild-type patients had a 70% rate.
• The clinical benefit rate (CBR) was 76% in all patients, 81% in patients with ESR1 mutations, and 74% in ESR1 wild-type patients.
• The overall response rate (ORR) was 27% among 37 response-evaluable patients with measurable disease, and 60% of these patients had a reduction in target lesion size.
• The combination was well-tolerated, with no new safety signals or increase in toxicity compared to ribociclib plus endocrine therapy.
• The company plans to initiate a Phase 3 trial (OPERA-02) of palazestrant in combination with ribociclib for first-line treatment of ER+/HER2advanced or metastatic breast cancer in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and regulatory progress, with a clear path forward for the company's key drug candidates. The financial position is also strong due to the recent capital raise. The sentiment is very positive, but not a perfect 10 due to the inherent risks in drug development.

Positives

• The FDA clearance of the IND application for OP-3136 allows the company to move forward with clinical trials for this novel KAT6 inhibitor.
• The combination of palazestrant and ribociclib demonstrated promising clinical activity, including tumor responses and prolonged disease stabilization.
• The 6-month PFS rate of 73% across all patients is encouraging, especially the 81% rate in ESR1 mutant patients.
• The combination was well-tolerated, with no new safety signals or increase in toxicity.
• The company is planning a Phase 3 trial (OPERA-02) for first-line treatment, indicating confidence in the combination's potential.
• The study showed a 27% ORR and 60% of patients with measurable disease had a reduction in target lesion size.
• The median PFS was not reached after a median follow-up of 12 months, suggesting a potential for long-term benefit.

Negatives

• The study is still ongoing, and the data is still maturing, so the final results may differ.
• The overall response rate (ORR) of 27% may be considered modest by some investors.
• The 6-month PFS rate of 68% in patients with prior CDK4/6i treatment is lower than the overall rate of 73%.

Risks

• The clinical trial results are preliminary and may not be indicative of future outcomes.
• The development of new drugs is subject to regulatory risks and uncertainties.
• The company may face challenges in enrolling patients for the planned Phase 3 trial.
• There is a risk that the combination therapy may not be as effective in a larger patient population.
• The company's financial position could be impacted by the costs of clinical trials and drug development.
• The competitive landscape in breast cancer treatment is intense, with other companies developing similar therapies.

Future Outlook

Olema plans to initiate a Phase 1 clinical trial for OP-3136 in early 2025 and a Phase 3 trial (OPERA-02) for palazestrant in combination with ribociclib in 2025. The company anticipates top-line data from the OPERA-01 Phase 3 trial in 2026 and a potential U.S. launch of palazestrant in 2027. The company is also focused on advancing its pipeline and exploring the potential of its therapies in other cancers.

Management Comments

• David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema Oncology, stated that the compelling activity demonstrated by OP-3136 in preclinical models has generated strong investigator interest.
• Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology, believes the data for palazestrant in combination with ribociclib are compelling and highly differentiated, with robust clinical activity shown across both ESR1 wild-type and mutant patient populations.
• Virginia Borges, M.D., Professor, Medicine-Medical Oncology at the University of Colorado, and Principal Investigator for the palazestrant plus ribociclib combination study, noted that the combination is well-tolerated with meaningful preliminary efficacy that has the potential to outperform the current standard of care.

Industry Context

The announcements are significant in the context of the breast cancer treatment landscape. The FDA clearance for OP-3136 represents a new approach to targeting KAT6, a validated epigenetic target. The positive results for palazestrant in combination with ribociclib suggest a potential new treatment option for patients with ER+/HER2advanced or metastatic breast cancer, particularly those with ESR1 mutations, which are a common resistance mechanism. The planned Phase 3 trial (OPERA-02) indicates a move towards establishing this combination as a first-line treatment.

Comparison to Industry Standards

• The 6-month PFS rate of 73% in all patients and 81% in ESR1 mutant patients for palazestrant plus ribociclib compares favorably to the MAINTAIN study of ribociclib plus endocrine therapy after CDK4/6i progression, which serves as a clinical benchmark.
• The MAINTAIN study showed a median PFS of 5.3 months for ribociclib plus endocrine therapy and 2.8 months for endocrine therapy alone, while the median PFS was not reached in the Olema study after a median follow-up of 12 months.
• The MORPHEUS study of giredestrant plus ribociclib showed a 6-month PFS rate of 58% in CDK4/6i pre-treated patients, which is lower than the 68% seen in the Olema study for a similar patient population.
• The safety profile of palazestrant plus ribociclib was consistent with the established safety profile of ribociclib plus endocrine therapy, which is a positive sign for its potential use in clinical practice.
• The overall response rate (ORR) of 27% in the Olema study is within the range of other combination therapies in this setting, but the 60% reduction in target lesion size is a notable finding.

Stakeholder Impact

• Shareholders: The positive clinical trial results and FDA clearance are likely to be viewed favorably by shareholders, potentially increasing the company's stock value.
• Patients: The development of new therapies for breast cancer could improve treatment options and outcomes for patients.
• Employees: The company's progress may boost employee morale and job security.
• Investors: The company's strong financial position and promising pipeline may attract new investors.
• Partners: The collaboration with Novartis for the OPERA-02 trial is a positive development for both companies.

Next Steps

• Initiate Phase 1 clinical trial for OP-3136 in early 2025.
• Initiate Phase 3 trial (OPERA-02) of palazestrant in combination with ribociclib in 2025.
• Continue the ongoing Phase 3 trial (OPERA-01) of palazestrant as a monotherapy.
• Share mature data from the palazestrant and ribociclib combination study in 2025.
• Prepare for potential commercial launch of palazestrant in 2027.

Key Dates

Keywords

breast cancer, palazestrant, ribociclib, OP-3136, KAT6 inhibitor, clinical trial, FDA, progression-free survival, endocrine therapy, metastatic breast cancer, ER+/HER2-, ESR1 mutation